Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Boehringer Ingelheim Pharma Gmbh & Co Kg
WARNING LETTER
•Boehringer Ingelheim Pharma Gmbh & Co Kg•November 12, 2012

Boehringer Ingelheim Pharma Gmbh & Co Kg – FDA Warning Letter, Nov 12, 2012

Record Details

On May 6, 2013, the FDA issued a Warning Letter to Boehringer-Ingelheim Pharma GmbH & Co. KG following a November 5-12, 2012 inspection of their API and finished pharmaceutical manufacturing facility in Ingelheim am Rhein, Germany. The inspection revealed significant violations of CGMP for APIs and finished pharmaceuticals (21 CFR Parts 210 and 211), rendering their products adulterated under Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act.

Key violations included the Quality Unit's failure to thoroughly investigate critical deviations, specifically foreign particles in the (b)(4) API. The firm acknowledged potential contamination in (b)(4) API batches from 2008 and 2009, with 22 of 29 identified particle types being (b)(4), yet used these contaminated lots for (b)(4) Capsules (b)(4) µg finished product. A formal project to address this began only in July 2012.

Additionally, the firm failed to conduct thorough complaint investigations regarding foreign particles in APIs, inconsistently concluding investigations as "confirmed" or "not confirmed" for similar issues. For finished products, the firm failed to reject drug products not meeting specifications, using API batches contaminated with foreign particles for (b)(4) Capsules (b)(4) µg manufacturing,

Company
Boehringer Ingelheim Pharma Gmbh & Co Kg
Inspection date
November 12, 2012
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Michael D. Smedley
View Company Profile

ID · 04e89218-3e9d-4810-a153-fa6ee72a013f

Violation Codes7
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)21 U.S.C. 356C(a)(1)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Boehringer Ingelheim Pharma Gmbh & Co Kg
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.